Cipla Limited (CIPLA) — Financial Results | 28 January 2025(3 announcements)
Cipla reported unaudited consolidated revenue of ₹7,072.97 crores for Q3 FY2025, up 32% YoY, with net profit at ₹1,574.59 crores, reflecting strong growth in pharmaceutical sales and new ventures. The Board approved results on 28 January 2025, highlighting operational momentum and strategic progress in discontinuing legacy businesses.
Cipla reported consolidated revenue of ₹7,073 crores for Q3 FY25, an 8% YoY increase, with EBITDA margin expanding to 28.1% and PAT rising 49.7% YoY to INR 1,571 crores, driven by growth across all geographies and improved operational efficiency.
Cipla reported consolidated net profit of ₹1,574.59 crore for Q3 FY2024, up 69.9% YoY, driven by revenue of ₹7,072.97 crore. The company faces NPPA demands of ₹2,011 crore but expects favorable resolution without provisioning. Tax provisions reversed by ₹155.61 crore due to ITAT orders. Paid-up capital rose to ₹161.52 crore post-share issuances. The Generics Business transferred to CPLS on February 29, 2024.
About Cipla Limited (CIPLA)
Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE
📡 Get AI alerts when CIPLA files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track CIPLA — Free💡 Ask AI about this filing
📊 More CIPLA filings
- Announcement — 11 August 2026 Cipla announced its ESG ratings from SES and NSE on August 11, 2026, showing a slight improvement in...
- Announcement — 4 August 2026 Cipla announced that its US subsidiary InvaGen closed a USFDA inspection at its Hauppauge facility, ...
- 🔴 Corporate Action — 31 July 2026 Cipla announced the allotment of 7,850 fully paid-up equity shares of INR 2 each under its ESOS 2013...
- Announcement — 27 July 2026 Cipla announced U.S. FDA approval for its generic version of Advair Diskus across all three strength...
- 🔴 Financial Results — 23 July 2026 Cipla reported consolidated revenue of INR 7,119 crores for Q1 FY27, up 2% YoY, with One India busin...
🔥 Also filed on 28 January 2025
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when CIPLA files new disclosures
Track CIPLA filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track CIPLA — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research